Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer

BJU International

Volumn 112, Issue 8, 2013, Pages 1105-1112

  Rieken, Malte ^a,b   Xylinas, Evanguelos ^a,c   Kluth, Luis ^a,d   Crivelli, Joseph J ^a   Chrystal, James ^a   Faison, Talia ^a   Lotan, Yair ^e   Karakiewicz, Pierre I ^f   Fajkovic, Harun ^h   Babjuk, Marek ^g,h   Kautzky Willer, Alexandra ^h   Bachmann, Alexander ^b   Scherr, Douglas S ^a   Shariat, Shahrokh F ^a,h  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c APHP Paris Descartes University ^*  (France)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

diabetes mellitus; metformin; non muscle invasive bladder cancer; outcomes

Indexed keywords

DOXORUBICIN; EPIRUBICIN; METFORMIN; MITOMYCIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURGERY; CAUSE OF DEATH; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE SURGERY; RECURRENT DISEASE; SINGLE DRUG DOSE; TRANSURETHRAL RESECTION OF BLADDER TUMOR; TREATMENT OUTCOME;

DIABETES MELLITUS; METFORMIN; NON-MUSCLE-INVASIVE BLADDER CANCER; OUTCOMES;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84887263940     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12448     Document Type: Article

References (32)

1. Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011; 59: 1009-1018
2. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59: 997-1008
3. MacKenzie T, Zens MS, Ferrara A, Schned A, Karagas MR,. Diabetes and risk of bladder cancer: evidence from a case-control study in New England. Cancer 2011; 117: 1552-1556
4. Newton CC, Gapstur SM, Campbell PT, Jacobs EJ,. Type 2 diabetes mellitus, insulin-use and risk of bladder cancer in a large cohort study. Int J Cancer 2013; 132: 2186-2191
5. Zhu Z, Zhang X, Shen Z, et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PLoS One 2013; 8: e56662
6. Hwang EC, Kim YJ, Hwang IS, et al. Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: a retrospective cohort study. Int J Urol 2011; 18: 769-776
7. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD,. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305
8. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ,. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33: 322-326
9. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010; 3: 1451-1461
10. Edge SB, Compton CC,. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-1474
11. Jeon JY, Jeong DH, Park MG, et al. Impact of diabetes on oncologic outcome of colorectal cancer patients: colon vs. rectal cancer. PLoS One 2013; 8: e55196
12. Zanders MM, Boll D, van Steenbergen LN, van de Poll-Franse LV, Haak HR,. Effect of diabetes on endometrial cancer recurrence and survival. Maturitas 2013; 74: 37-43
13. Snyder CF, Stein KB, Barone BB, et al. Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis 2010; 13: 58-64
14. Varlotto J, Medford-Davis LN, Recht A, et al. Confirmation of the role of diabetes in the local recurrence of surgically resected non-small cell lung cancer. Lung Cancer 2012; 75: 381-390
15. Oh JJ, Hong SK, Lee S, Sohn SJ, Lee SE,. Diabetes mellitus is associated with short prostate-specific antigen doubling time after radical prostatectomy. Int Urol Nephrol 2013; 45: 121-127
16. van de Poll-Franse LV, Haak HR, Coebergh JW, Janssen-Heijnen ML, Lemmens VE,. Disease-specific mortality among stage I-III colorectal cancer patients with diabetes: a large population-based analysis. Diabetologia 2012; 55: 2163-2172
17. Liu S, Li Y, Lin T, Fan X, Liang Y, Heemann U,. High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt. Diabetes Res Clin Pract 2011; 91: 177-182
18. Rochester MA, Patel N, Turney BW, et al. The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer. BJU Int 2007; 100: 1396-1401
19. Metalli D, Lovat F, Tripodi F, et al. The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol 2010; 176: 2997-3006
20. Sun HZ, Wu SF, Tu ZH,. Blockage of IGF-1R signaling sensitizes urinary bladder cancer cells to mitomycin-mediated cytotoxicity. Cell Res 2001; 11: 107-115
21. Liang PI, Wang YH, Wu TF, et al. IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder. J Clin Pathol 2013; 66: 573-582
22. Colmers IN, Bowker SL, Majumdar SR, Johnson JA,. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012; 184: E675-683
23. Mamtani R, Haynes K, Bilker WB, et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst 2012; 104: 1411-1421
24. Hillaire-Buys D, Faillie JL, Montastruc JL,. Pioglitazone and bladder cancer. Lancet 2011; 378: 1543-1544; author reply 1544-5
25. Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ,. Metformin and Prostate Cancer: reduced Development of Castration-resistant Disease and Prostate Cancer Mortality. Eur Urol 2013; 63: 709-716
26. Romero IL, McCormick A, McEwen KA, et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol 2012; 119: 61-67
27. Tan BX, Yao WX, Ge J, et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer 2011; 117: 5103-5111
28. Jalving M, Gietema JA, Lefrandt JD, et al. Metformin: taking away the candy for cancer? Eur J Cancer 2010; 46: 2369-2380
29. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D,. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012; 18: 2905-2912
30. Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH,. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 2012; 131: 752-759
31. He XX, Tu SM, Lee MH, Yeung SC,. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 2011; 22: 2640-2645
32. Noon AP, Albertsen PC, Thomas F, Rosario DJ, Catto JW,. Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients. Br J Cancer 2013; 108: 1534-1540